Ionis says Roche Phase 3 IMAgINATION interim data show sefaxersen cuts proteinuria in IgA nephropathy

• Ionis reported positive prespecified interim Phase 3 IMAgINATION results for Roche-partnered sefaxersen in adults with primary IgA nephropathy.
• The interim findings have not yet been presented; Roche plans to present them at an upcoming medical meeting.
• Sefaxersen reduced signs of kidney damage versus placebo, supporting its potential to slow disease progression.
• Safety was consistent with earlier data, with no new safety signals.
• The blinded study continues, with a longer-term kidney function readout expected at week 105.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609230100BIZWIRE_USPR_____20260922_BW857250) on September 23, 2026, and is solely responsible for the information contained therein.